Cargando…
Boosting Adaptive Immunity: A New Role for PAFR Antagonists
We have previously shown that the Platelet-Activating Factor Receptor (PAFR) engagement in murine macrophages and dendritic cells (DCs) promotes a tolerogenic phenotype reversed by PAFR-antagonists treatment in vitro. Here, we investigated whether a PAFR antagonist would modulate the immune response...
Autores principales: | Koga, Marianna M., Bizzarro, Bruna, Sá-Nunes, Anderson, Rios, Francisco J., Jancar, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155422/ https://www.ncbi.nlm.nih.gov/pubmed/27966635 http://dx.doi.org/10.1038/srep39146 |
Ejemplares similares
-
Oxidized LDL Induces Alternative Macrophage Phenotype through Activation of CD36 and PAFR
por: Rios, Francisco J., et al.
Publicado: (2013) -
Co-Stimulation of PAFR and CD36 Is Required for oxLDL-Induced Human Macrophages Activation
por: Rios, Francisco J. O., et al.
Publicado: (2012) -
Uptake of oxLDL and IL-10 Production by Macrophages Requires PAFR and CD36 Recruitment into the Same Lipid Rafts
por: Rios, Francisco J. O., et al.
Publicado: (2013) -
Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma
por: Onuchic, Ana Claudia, et al.
Publicado: (2012) -
PAFR activation of NF-κB p65 or p105 precursor dictates pro- and anti-inflammatory responses during TLR activation in murine macrophages
por: Ishizuka, Edson K., et al.
Publicado: (2016)